Human skin replacement - Amarantus Bioscience

Drug Profile

Human skin replacement - Amarantus Bioscience

Alternative Names: Cultured skin substitute - Amarantus Bioscience; Engineered skin substitute - Amarantus Bioscience; ESS-W; PermaDerm

Latest Information Update: 05 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lonza
  • Developer Amarantus Bioscience Holdings
  • Class Cell therapies
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Burns
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Burns
  • Clinical Phase Unknown Nevus

Most Recent Events

  • 01 Dec 2017 Human skin replacement is still undergoing clinical development for Nevus in USA
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Nevus(In children, In infants) in USA (Topical)
  • 13 Sep 2016 Phase-II clinical trials in Burns in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top